Day, Fiona http://orcid.org/0000-0002-5905-9408
Sridharan, Swetha
Lynam, James
Gedye, Craig
Johnson, Catherine
Fraser, Allison
Thompson, Stephen R.
Michael, Michael
Leong, Trevor
Roy, Amitesh
Kumar, Mahesh
van der Westhuizen, Andre
Quah, Gaik T.
Mandaliya, Hiren
Mallesara, Girish
Sappiatzer, Joshua
Oldmeadow, Christopher
Martin, Jarad
Article History
Received: 22 September 2022
Accepted: 5 December 2022
First Online: 17 December 2022
Declarations
:
: Institutional ethics approval is required to conduct this clinical trial, and patients will provide written, informed consent. Central ethics approval (2019/ETH12056) was obtained from the Hunter New England Human Research Ethics Committee, Newcastle, Australia. The current approved protocol is version 5, dated 28 June 2022.
: Not applicable.
: Durvalumab used in this study is provided by AstraZeneca. CJ and AF declare financial competing interests. All other authors declare no competing interests.